Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2007
Discovery of a small molecule antagonist of the parathyroid hormone receptor by using an N-terminal parathyroid hormone peptide probePercy H Carter, Rui-Qin Liu, William R Foster, et al.
The Journal of Experimental Medicine|April 11, 2022
CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinomaJianxin Wang, May Tun Saung, Keyu Li, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
gamma-Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonistsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.
ACS Medicinal Chemistry Letters|November 19, 2021
BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical CandidateRobert J Cherney, Prakash Anjanappa, Kumaravel Selvakumar, et al.
Journal for Immunotherapy of Cancer|March 10, 2022
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironmentNatalie B Collins, Rose Al Abosy, Brian C Miller, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonistsBin Jiang, James J-W Duan, Sylwia Stachura, et al.
Ebiomedicine|March 9, 2026
Integrating breast tumour homologous recombination deficiency status to aid germline BRCA1 and BRCA2 variant classificationCristina Fortuno, Jia Zhang, Lambros T Koufariotis, et al.
ACS Medicinal Chemistry Letters|April 21, 2015
Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5Percy H Carter, Gregory D Brown, Robert J Cherney, et al.
Pageof 12